CN101590208B - Medicament composition for treating rheumatoid arthritis, and preparation method thereof - Google Patents
Medicament composition for treating rheumatoid arthritis, and preparation method thereof Download PDFInfo
- Publication number
- CN101590208B CN101590208B CN2009100595232A CN200910059523A CN101590208B CN 101590208 B CN101590208 B CN 101590208B CN 2009100595232 A CN2009100595232 A CN 2009100595232A CN 200910059523 A CN200910059523 A CN 200910059523A CN 101590208 B CN101590208 B CN 101590208B
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- scorpio
- medicament
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 title abstract description 26
- 238000002360 preparation method Methods 0.000 title abstract description 13
- 239000000203 mixture Substances 0.000 title abstract description 4
- 241000522620 Scorpio Species 0.000 claims abstract description 40
- 239000009490 scorpio Substances 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 241001251068 Formica fusca Species 0.000 claims description 17
- 239000000284 extract Substances 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 241000545442 Radix Species 0.000 claims description 3
- 238000007796 conventional method Methods 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 20
- 208000002193 Pain Diseases 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 4
- 230000008961 swelling Effects 0.000 abstract description 2
- 244000163122 Curcuma domestica Species 0.000 abstract 1
- 235000003392 Curcuma domestica Nutrition 0.000 abstract 1
- 244000287680 Garcinia dulcis Species 0.000 abstract 1
- 241000501743 Gentiana macrophylla Species 0.000 abstract 1
- 241001166194 Geranium wilfordii Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 241000257303 Hymenoptera Species 0.000 abstract 1
- 241000218164 Menispermaceae Species 0.000 abstract 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 abstract 1
- 241000830536 Tripterygium wilfordii Species 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 235000003373 curcuma longa Nutrition 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 235000015398 thunder god vine Nutrition 0.000 abstract 1
- 235000013976 turmeric Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000001035 drying Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 241000218176 Corydalis Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 231100000862 numbness Toxicity 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000019890 Amylum Nutrition 0.000 description 1
- 206010068975 Bone atrophy Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000026214 Skeletal muscle atrophy Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- VXIHRIQNJCRFQX-UHFFFAOYSA-K disodium aurothiomalate Chemical compound [Na+].[Na+].[O-]C(=O)CC(S[Au])C([O-])=O VXIHRIQNJCRFQX-UHFFFAOYSA-K 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940074869 marquis Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000025185 skeletal muscle atrophy Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicament composition for treating rheumatoid arthritis, which is a preparation mainly prepared from the raw materials such as black ants, tripterygium wilfordii, scorpio, geranium wilfordii, rhizoma dioscoreae nipponicae, menispermaceae roots, gentiana macrophylla, turmeric and liquorice. The medicament has the advantages of simple and unique prescription, low price and remarkable efficacy. Clinical study confirms that the medicament can rapidly improve pain, swelling, morning stiffness symptoms of patients without obvious toxic-side effects. The invention also discloses a method for preparing the medicament. The medicament is obtained by grinding or extracting Chinese medicaments with solvents respectively, performing other pretreatment and then compounding the obtained products pro rata according to the different characteristics of each Chinese medicament.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition of treating rheumatoid arthritis.Be the Chinese patent medicine that primary raw material is prepared from Formica fusca, Radix Tripterygii Wilfordii, Scorpio (Scorpio), Herba Erodii, Rhizoma Dioscoreae Nipponicae, Radix Stephaniae Tetrandrae, Radix Gentianae Macrophyllae, Rhizoma Curcumae Longae, Radix Glycyrrhizae specifically.The invention still further relates to manufacturing method for above mentioned medicine.
Background technology
Rheumatoid arthritis is claimed rheumatoid (RA) again, is the not clear as yet chronic systemic inflammatory property disease of a kind of cause of disease, is main clinical manifestation with pathological changes outside chronic, symmetry, many synovial jointss inflammation and the joint, belongs to the autoimmune inflammatory diseases.This disease is sent out well in little joints such as hands, wrist, foots, and outbreak is symmetrical distribution repeatedly.Joint red and swollen heat pain and dysfunction are arranged in early days, and late period, stiff deformity in various degree can appear in the joint, and with bone and skeletal muscle atrophy, very easily disabled.
Rheumatoid arthritis does not still have specific short so far, still stays in the treatment to inflammation and sequela, takes Comprehensive Treatment, and most of patients all can obtain certain curative effect.The purpose of existing treatment is: 1. control the inflammation of joint and other tissue, relief of symptoms; 2. keep function of joint and prevent deformity; 3. repair impaired joint to ease the pain and restore funcitons.Drug therapy is main with Western medicine mainly: 1, nonsteroidal antiinflammatory drug (NSAIDS): be used for just sending out or light disease case, have the effect of anti-inflammatory analgetic.But the natural process that can not stop rheumatoid arthritis to become; 2. golden preparation: rheumatoid arthritis is had sure curative effect, Kidon (Ono) commonly used; 3, immunosuppressant: be useful in the invalid serious patient with rheumatoid arthritis of other medicines, like methotrexate (MTX) etc.; 4, adrenocortical hormone: to arthralgia, control inflammation, the anti-inflammatory analgetic effect is rapid, but effect is not lasting, and the cause of disease and pathogeny are had no effect.Though said medicine has certain curative effect, side effect is more, and motherland's medical science has accumulated invaluable experience in this respect, and therefore, the Chinese medicine preparation that exploitation has determined curative effect, few side effects has bright development prospect.
Summary of the invention
The object of the present invention is to provide a kind of Chinese medicine and corresponding preparations thereof of treating the rheumatoid arthritis determined curative effect.Its characteristics have: can comparatively fast improve patient's the stiff symptom of pain, swelling, morning, and low price, no obvious toxic-side effects.
Rheumatoid arthritis belongs to the traditional Chinese medical science " numbness is sick ".Etiology and pathogenesis is the damp that is affected by the cold, numbness resistance meridians, and QI-blood circulation is not smooth, causes muscle, muscles and bones, arthralgia, numbness, movable distortion.Solution of the present invention is based on the pathogenetic understanding of motherland's medical science to rheumatoid arthritis; According to oneself clinical experience for many years; From numerous Chinese medicines, confirm the effective Chinese medicine of a series of treatment rheumatoid arthritiss earlier, through clinical repeated validation, screen compound Chinese medicinal preparation again.Effect with dispelling wind and removing obstruction in the collateral, promoting blood circulation and stopping pain.
The present invention is a kind of pharmaceutical composition of treating rheumatoid arthritis, it is characterized in that it comprises Formica fusca, Radix Tripterygii Wilfordii, Scorpio (Scorpio), Herba Erodii, Rhizoma Dioscoreae Nipponicae, Radix Stephaniae Tetrandrae, Radix Gentianae Macrophyllae, Rhizoma Curcumae Longae, Radix Glycyrrhizae nine herbal medicines.
Medicine composition of the present invention can also contain one or more in the Chinese medicines such as Rhizoma Corydalis Decumbentis, Herba Asari, Semen Coicis, Rhizoma Atractylodis.
Medicine of the present invention can be the medicine of said dosage form on any pharmaceutics.
The preparation of this medicine can prepare by the conventional method on the various medicaments, as:
Formica fusca is broken into fine powder; Or Formica fusca, Radix Tripterygii Wilfordii, Scorpio (Scorpio), Herba Erodii, Rhizoma Dioscoreae Nipponicae, Radix Stephaniae Tetrandrae, Radix Gentianae Macrophyllae, Rhizoma Curcumae Longae extracted by conventional method with ethanol or water etc., concentrating, drying is processed the medicine of required dosage form.
In the above preparation process, if necessary, can add adjuvant commonly used in an amount of pharmaceutics, like starch, dextrin, microcrystalline cellulose, amylum pregelatinisatum, magnesium stearate, micropowder silica gel, sucrose, carboxymethyl starch sodium etc.
For showing clinical effectiveness of the present invention; Select 18～65 years old, be diagnosed as patient's 72 examples of rheumatoid arthritis, diagnostic criteria is by Americanism damp disease association diagnosis of rheumatoid arthritis standard in 1987, function of joint classification I-III level; The joint is I-III phase by stages, the course of disease 6 months～5 years.Random packet is carried out observation of curative effect.Chinese medicine preparation group (test group) 69 examples, male 25 examples, women 44 examples, 46 ± 11 years old age; Glucosidorum Tripterygll Totorum (matched group) 34 examples, male 14 examples, women 20 examples, at 43 ± 9 years old age, test group and matched group are having good comparability aspect age, sex, the course of disease and the state of an illness.
Therapeutic Method: the treatment group gives Chinese medicine preparation 20g/ day, divide 3 times oral; Matched group gives Glucosidorum Tripterygll Totorum each 20mg, and 3 times on the one, equal 8 weeks are 1 course of treatment.
Curative effect of disease: test group produce effects 11 examples (15.94%), progressive 14 examples (20.29%), effective 31 examples (44.93%), invalid 13 examples (18.84%), total effective rate 81.16%; Matched group produce effects 5 examples (14.71%), progressive 8 examples (23.53%), effective 13 examples (38.23%), invalid 8 examples (23.53%), total effective rate is 76.47%.Difference not statistically significant (P＞0.05).
Syndrome in TCM marquis's therapeutic evaluation: test group clinical cure 15 examples (21.74%), produce effects 21 examples (30.43%), effective 24 examples (34.78%), invalid 9 examples (13.04%), total effective rate 86.96%; Matched group clinical cure 7 examples (20.59%), produce effects 9 examples (26.47%), effective 12 examples (35.29%), invalid 6 examples (17.65%), total effective rate 82.35%, two group difference not statistically significant.
Two groups all can be reduced arthritis parameter (ESR, CRP, RF) level, but aspect stiff time in morning, the doing well,improving that swells and ache, test group is superior to matched group, and difference has statistical significance.
Through observing, test group has 1 example, and matched group has the stomach discomfort symptom of 2 routine had slight, does not see obvious adverse reaction and toxic and side effects after all the other patients take medicine.
The specific embodiment
The present invention forms as follows by weight ratio:
Formica fusca 10-40 part, Radix Tripterygii Wilfordii 10-30 part, Rhizoma Curcumae Longae 5-20 part, Herba Erodii 10-30 part, Scorpio (Scorpio) 1-5 part, Radix Glycyrrhizae 1-10 part, Rhizoma Dioscoreae Nipponicae 10-30 part, Radix Stephaniae Tetrandrae 10-20 part, Radix Gentianae Macrophyllae 10-20 part.
Preferred weight proportioning of the present invention is:
Formica fusca 10-25 part, Radix Tripterygii Wilfordii 10-20 part, Rhizoma Curcumae Longae 5-10 part, Herba Erodii 10-20 part, Scorpio (Scorpio) 1-5 part, Radix Glycyrrhizae 1-5 part, Rhizoma Dioscoreae Nipponicae 10-20 part, Radix Stephaniae Tetrandrae 5-10 part, Radix Gentianae Macrophyllae 5-10 part.
The method for preparing of medicine of the present invention is an example for 7.5 parts with 25 parts of Formica fuscas, 15 parts of Radix Tripterygii Wilfordiis, 7.5 parts in Rhizoma Curcumae Longae, 15 parts of Herba Erodiis, 2.5 parts of Scorpios (Scorpio), 5 parts in Radix Glycyrrhizae, 15 parts of Rhizoma Dioscoreae Nipponicae, 7.5 parts of Radixs Stephaniae Tetrandrae, Radix Gentianae Macrophyllae, can be with reference to following method:
(1) directly Scorpio (Scorpio) is ground into fine powder; Formica fusca, Radix Tripterygii Wilfordii, Herba Erodii, Rhizoma Dioscoreae Nipponicae, Radix Stephaniae Tetrandrae, Radix Gentianae Macrophyllae, Rhizoma Curcumae Longae, Radix Glycyrrhizae water are pressed decocting method extract, concentrate, drying gets extract, then Scorpio (Scorpio) fine powder is mixed with extract evenly, granulates, and is processed into tablet.
(2) directly Scorpio (Scorpio) is ground into fine powder; Formica fusca, Radix Tripterygii Wilfordii, Herba Erodii, Rhizoma Dioscoreae Nipponicae, Radix Stephaniae Tetrandrae, Radix Gentianae Macrophyllae, Rhizoma Curcumae Longae, Radix Glycyrrhizae water are pressed decocting method extract, concentrate, drying gets extract, then Scorpio (Scorpio) fine powder is mixed evenly with extract. granulate. and filling, be processed into capsule.
(3) directly Scorpio (Scorpio) is ground into fine powder; Formica fusca, Radix Tripterygii Wilfordii, Herba Erodii, Rhizoma Dioscoreae Nipponicae, Radix Stephaniae Tetrandrae, Radix Gentianae Macrophyllae, Rhizoma Curcumae Longae, Radix Glycyrrhizae water are pressed decocting method extract, concentrate, drying gets extract, then Scorpio (Scorpio) fine powder is mixed with extract evenly, granulates, and is processed into granule.
(4) directly Scorpio (Scorpio) is ground into fine powder; Radix Tripterygii Wilfordii is used alcohol reflux; Formica fusca, Herba Erodii, Rhizoma Dioscoreae Nipponicae, Radix Stephaniae Tetrandrae, Radix Gentianae Macrophyllae, Rhizoma Curcumae Longae, Radix Glycyrrhizae water are pressed decocting method extract, concentrate drying; Get extract,, granulate then with Scorpio (Scorpio) fine powder, Radix Tripterygii Wilfordii ethanol extract and water extract mix homogeneously; Capsule is processed in filling.
And for example, consumption consists of: the preparation of 20 parts of Formica fuscas, 13 parts of Radix Tripterygii Wilfordiis, 6 parts in Rhizoma Curcumae Longae, 13 parts of Herba Erodiis, 2 parts of Scorpios (Scorpio), 2 parts in Radix Glycyrrhizae, 13 parts of Rhizoma Dioscoreae Nipponicae, 5 parts of Radixs Stephaniae Tetrandrae, 6 parts of Radix Gentianae Macrophyllae, Rhizoma Corydalis Decumbentis 6, Herba Asari 4, Semen Coicis 6, Rhizoma Atractylodis 4.Its preparation method is:
Directly Scorpio (Scorpio) is ground into fine powder; Formica fusca, Radix Tripterygii Wilfordii, Herba Erodii, Rhizoma Dioscoreae Nipponicae, Radix Stephaniae Tetrandrae, Radix Gentianae Macrophyllae, Rhizoma Curcumae Longae, Radix Glycyrrhizae, Rhizoma Corydalis Decumbentis, Herba Asari, Semen Coicis, Rhizoma Atractylodis water are pressed decocting method to be extracted; Concentrate; Drying gets extract, then Scorpio (Scorpio) fine powder is mixed with extract evenly; Granulate, be processed into granule or tablet or capsule.
Claims (5)
1. a pharmaceutical composition of treating rheumatoid arthritis is characterized in that it is to be processed by following raw materials by weight proportions: Formica fusca 10-40 part, Radix Tripterygii Wilfordii 10-30 part, Rhizoma Curcumae Longae 5-20 part, Herba Erodii 10-30 part, Scorpio 1-5 part, Radix Glycyrrhizae 1-10 part, Rhizoma Dioscoreae Nipponicae 10-30 part, Radix Stephaniae Tetrandrae 10-20 part, Radix Gentianae Macrophyllae 10-20 part.
2. a pharmaceutical composition of treating rheumatoid arthritis is characterized in that it is to be processed by following raw materials by weight proportions: Formica fusca 10-25 part, Radix Tripterygii Wilfordii 10-20 part, Rhizoma Curcumae Longae 5-10 part, Herba Erodii 10-20 part, Scorpio 1-5 part, Radix Glycyrrhizae 1-5 part, Rhizoma Dioscoreae Nipponicae 10-20 part, Radix Stephaniae Tetrandrae 5-10 part, Radix Gentianae Macrophyllae 5-10 part.
3. pharmaceutical composition according to claim 2 is characterized in that it is to be processed by following raw materials by weight proportions: 25 parts of Formica fuscas, 15 parts of Radix Tripterygii Wilfordiis, 7.5 parts in Rhizoma Curcumae Longae, 15 parts of Herba Erodiis, 2.5 parts of Scorpios, 5 parts in Radix Glycyrrhizae, 15 parts of Rhizoma Dioscoreae Nipponicae, 7.5 parts of Radixs Stephaniae Tetrandrae, 7.5 parts of Radix Gentianae Macrophyllae.
4. according to each described pharmaceutical composition in the claim 1 to 3, it is characterized in that the dosage form of said pharmaceutical composition is selected from granule or tablet or capsule.
5. prepare the method for each described pharmaceutical composition in the claim 1 to 3, it is characterized in that: Scorpio is ground into fine powder; Formica fusca, Radix Tripterygii Wilfordii, Herba Erodii, Rhizoma Dioscoreae Nipponicae, Radix Stephaniae Tetrandrae, Radix Gentianae Macrophyllae, Rhizoma Curcumae Longae, Radix Glycyrrhizae water are extracted by conventional method, concentrated, dry, then with extract and Scorpio fine powder mixing, add adjuvant, process required dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100595232A CN101590208B (en) | 2009-06-08 | 2009-06-08 | Medicament composition for treating rheumatoid arthritis, and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100595232A CN101590208B (en) | 2009-06-08 | 2009-06-08 | Medicament composition for treating rheumatoid arthritis, and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101590208A CN101590208A (en) | 2009-12-02 |
| CN101590208B true CN101590208B (en) | 2012-01-18 |
Family
ID=41405208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100595232A Expired - Fee Related CN101590208B (en) | 2009-06-08 | 2009-06-08 | Medicament composition for treating rheumatoid arthritis, and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101590208B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105561186A (en) * | 2015-12-31 | 2016-05-11 | 张茂全 | Traditional Chinese medicine formula for treating rheumatoid arthritis |
| CN105709119A (en) * | 2016-04-18 | 2016-06-29 | 青岛海澄知识产权事务有限公司 | Composition for treating rheumatoid arthritis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1876157A (en) * | 2006-04-27 | 2006-12-13 | 张启栋 | A medicinal wine for treating rheumatic and rheumatoid disease |
-
2009
- 2009-06-08 CN CN2009100595232A patent/CN101590208B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1876157A (en) * | 2006-04-27 | 2006-12-13 | 张启栋 | A medicinal wine for treating rheumatic and rheumatoid disease |
Non-Patent Citations (2)
| Title |
|---|
| 丁波.类风湿性关节炎的中医治疗进展.《临床误诊误治》.2008,第21卷(第5期),第87-88页. * |
| 刘德泉,等.痹症用药规律探讨.《实用中西医结合杂志》.1997,第10卷(第21期),第2065-2066页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101590208A (en) | 2009-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101229300B (en) | Chinese traditional medicine preparation for treating bone fracture | |
| CN101912575B (en) | External medicament for treating painful swelling of joints and gout diseases and preparation process thereof | |
| CN101011544A (en) | Gout rapid recovery pill(capsule) and preparation technique thereof | |
| CN101095856A (en) | Chinese traditional medicine for treating anaphylactoid purpura nephritis | |
| CN103285330B (en) | Traditional Chinese medicine for treating uterine fibroid and preparation method thereof | |
| CN101590208B (en) | Medicament composition for treating rheumatoid arthritis, and preparation method thereof | |
| CN108295128B (en) | Traditional Chinese medicine compound preparation for treating rheumatoid arthritis and preparation method thereof | |
| CN104524247B (en) | One treats migrainous medical composition and its use | |
| CN101002848B (en) | Medicine for treating recurrent uarthritis, and its preparing method | |
| CN101002873A (en) | Medicine for treating recurrent gout, and its preparing method | |
| CN114632128A (en) | Collateral-dredging and turbid-removing formula and using method thereof | |
| CN1712055A (en) | Chinese medicinal preparation (litholytic capsule) for treating urinific calculus | |
| CN101024029B (en) | Medicine for treating bony arthritis, rheumatism arthritis | |
| CN103566241A (en) | Traditional Chinese medicinal composition for treating diarrhea | |
| CN102755598B (en) | Medicine for treating acute gouty arthritis and preparation method thereof | |
| CN102836346B (en) | Traditional Chinese medicine for treating lumbar disc herniation | |
| CN103263572B (en) | Traditional Chinese medicine composition for treating osteoporosis and preparation method thereof | |
| CN102600251A (en) | Compound rheumatism-rehabilitating composite agent | |
| CN1304032C (en) | Prostate proliferation treating medicine composition | |
| CN1872165A (en) | A medicine combination, preparation method and method for controlling quality | |
| CN105288344A (en) | Traditional Chinese medicinal composition for treating liver and gall calculi, and application thereof | |
| CN105617161A (en) | Traditional Chinese medicine composition for treating gout | |
| CN104435149A (en) | Traditional Chinese medicine composition containing kadsura pepper stem for treating gout | |
| CN104491765B (en) | A kind of medical composition and its use for the treatment of nodules of the breast | |
| CN111150825A (en) | A Chinese medicinal composition for treating rheumatism and gout |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: YONGKANG PHARMACEUTICAL CO., LTD., CHENGDU Free format text: FORMER OWNER: GUO KAI Effective date: 20120418 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 610045 CHENGDU, SICHUAN PROVINCE TO: 611130 CHENGDU, SICHUAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20120418 Address after: 611130 Yongkang Road, Wenjiang District, Sichuan, No. 688, No. Patentee after: Yongkang Pharmaceutical Co., Ltd., Chengdu Address before: 610045 Sichuan city of Chengdu province Wuhou District Wu Xing Road No. 2 Notting Hill No. 8-6-1002 Patentee before: Guo Kai |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicine composition for treating rheumatoid arthritis and preparation method of medicine composition Effective date of registration: 20130422 Granted publication date: 20120118 Pledgee: Shanghai Pudong Development Bank Chengdu branch of Limited by Share Ltd Tongjin Pledgor: Yongkang Pharmaceutical Co., Ltd., Chengdu Registration number: 2013990000223 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20160926 Granted publication date: 20120118 Pledgee: Shanghai Pudong Development Bank Chengdu branch of Limited by Share Ltd Tongjin Pledgor: Yongkang Pharmaceutical Co., Ltd., Chengdu Registration number: 2013990000223 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20161201 Address after: 610045 Sichuan city of Chengdu province Wuhou District Wu Xing Road No. 2 Notting Hill No. 8-6-1002 Patentee after: Guo Kai Address before: 611130 Yongkang Road, Wenjiang District, Sichuan, No. 688, No. Patentee before: Yongkang Pharmaceutical Co., Ltd., Chengdu |
|
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: 610041 Chengdu City, Sichuan province high tech Zone, Century City Road, Longhu century Feng Jing, building 1, unit 3703, 7 Patentee after: Guo Kai Address before: 610045 Sichuan city of Chengdu province Wuhou District Wu Xing Road No. 2 Notting Hill No. 8-6-1002 Patentee before: Guo Kai |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120118 Termination date: 20170608 |